T. Rowe Price Associates
JAZZ icon

T. Rowe Price Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

T. Rowe Price Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
55,928
+5,968
+12% +$1.04M ﹤0.01% 1203
2025
Q4 		$8.49M Buy
49,960
+3,256
+7% +$499K ﹤0.01% 1258
2025
Q3 		$6.16M Buy
46,704
+2,640
+6% +$317K ﹤0.01% 1341
2025
Q2 		$4.68M Buy
44,064
+1,625
+4% +$177K ﹤0.01% 1291
2025
Q1 		$5.27M Buy
42,439
+4,255
+11% +$555K ﹤0.01% 1245
2024
Q4 		$4.7M Buy
38,184
+1,041
+3% +$123K ﹤0.01% 1307
2024
Q3 		$4.14M Buy
37,143
+3,003
+9% +$329K ﹤0.01% 1356
2024
Q2 		$3.64M Buy
34,140
+1,317
+4% +$145K ﹤0.01% 1324
2024
Q1 		$3.95M Sell
32,823
-15,521
-32% -$1.9M ﹤0.01% 1291
2023
Q4 		$5.95M Buy
48,344
+18,796
+64% +$2.35M ﹤0.01% 1174
2023
Q3 		$3.83M Sell
29,548
-681
-2% -$90.7K ﹤0.01% 1245
2023
Q2 		$3.75M Sell
30,229
-253
-0.8% -$34K ﹤0.01% 1262
2023
Q1 		$4.46M Sell
30,482
-2,481
-8% -$367K ﹤0.01% 1211
2022
Q4 		$5.25M Buy
32,963
+911
+3% +$134K ﹤0.01% 1180
2022
Q3 		$4.27M Buy
32,052
+5,336
+20% +$811K ﹤0.01% 1235
2022
Q2 		$4.17M Buy
26,716
+350
+1% +$53.9K ﹤0.01% 1448
2022
Q1 		$4.1M Buy
26,366
+2,563
+11% +$372K ﹤0.01% 1494
2021
Q4 		$3.03M Sell
23,803
-4,732
-17% -$622K ﹤0.01% 1580
2021
Q3 		$3.72M Buy
28,535
+220
+0.8% +$33.2K ﹤0.01% 1553
2021
Q2 		$5.03M Buy
28,315
+3,412
+14% +$591K ﹤0.01% 1503
2021
Q1 		$4.09M Sell
24,903
-380,467
-94% -$62.6M ﹤0.01% 1513
2020
Q4 		$66.9M Sell
405,370
-149,088
-27% -$22.2M 0.01% 855
2020
Q3 		$79.1M Sell
554,458
-181,895
-25% -$22.6M 0.01% 724
2020
Q2 		$81.2M Buy
736,353
+10,822
+1% +$1.2M 0.01% 697
2020
Q1 		$72.4M Buy
725,531
+504,217
+228% +$65.2M 0.01% 667
2019
Q4 		$33M Buy
221,314
+2,915
+1% +$397K ﹤0.01% 1039
2019
Q3 		$28M Buy
218,399
+7,087
+3% +$950K ﹤0.01% 1047
2019
Q2 		$30.1M Sell
211,312
-1,991
-0.9% -$268K ﹤0.01% 1047
2019
Q1 		$30.5M Buy
213,303
+11,741
+6% +$1.53M ﹤0.01% 1040
2018
Q4 		$25M Buy
201,562
+4,338
+2% +$644K ﹤0.01% 1075
2018
Q3 		$33.2M Sell
197,224
-227,469
-54% -$39.1M ﹤0.01% 1057
2018
Q2 		$73.2M Buy
424,693
+37,431
+10% +$6.12M 0.01% 754
2018
Q1 		$58.5M Buy
387,262
+225,751
+140% +$33.1M 0.01% 815
2017
Q4 		$21.7M Buy
161,511
+2,094
+1% +$290K ﹤0.01% 1160
2017
Q3 		$23.3M Sell
159,417
-34,616
-18% -$5.24M ﹤0.01% 1127
2017
Q2 		$30.2M Buy
194,033
+59,073
+44% +$9.03M 0.01% 1018
2017
Q1 		$19.6M Buy
134,960
+19,980
+17% +$2.6M ﹤0.01% 1172
2016
Q4 		$12.5M Buy
114,980
+6,750
+6% +$752K ﹤0.01% 1268
2016
Q3 		$13.1M Buy
108,230
+3,130
+3% +$422K ﹤0.01% 1257
2016
Q2 		$14.9M Sell
105,100
-2,607
-2% -$384K ﹤0.01% 1189
2016
Q1 		$14.1M Sell
107,707
-270,857
-72% -$33.7M ﹤0.01% 1185
2015
Q4 		$53.2M Sell
378,564
-9,673
-2% -$1.34M 0.01% 744
2015
Q3 		$51.6M Sell
388,237
-5,563
-1% -$958K 0.01% 761
2015
Q2 		$69.3M Buy
393,800
+100
+0% +$18K 0.01% 725
2015
Q1 		$68M Sell
393,700
-1,400
-0.4% -$240K 0.01% 735
2014
Q4 		$64.7M Sell
395,100
-6,700
-2% -$1.11M 0.01% 749
2014
Q3 		$64.5M Sell
401,800
-88,400
-18% -$13.6M 0.01% 745
2014
Q2 		$72.1M Sell
490,200
-439,150
-47% -$60.9M 0.02% 735
2014
Q1 		$129M Sell
929,350
-65,150
-7% -$9.81M 0.03% 561
2013
Q4 		$126M Sell
994,500
-4,200
-0.4% -$435K 0.03% 547
2013
Q3 		$91.8M Buy
998,700
+10,500
+1% +$847K 0.02% 613
2013
Q2 		$67.9M Buy
+988,200
New +$60.4M 0.02% 691

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates's JAZZ Position: Q1 2026 in Review

T. Rowe Price Associates increased its Jazz Pharmaceuticals (JAZZ) stake by 12% in Q1 2026, buying an estimated $1.04M and bringing the position to 55,928 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1203.

T. Rowe Price Associates first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $129M in Q1 2014. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • T. Rowe Price Associates held 55,928 shares of Jazz Pharmaceuticals worth $10.6M as of Q1 2026.
  • T. Rowe Price Associates bought 5,968 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.04M.
  • Jazz Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1203 holding.
  • T. Rowe Price Associates first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Jazz Pharmaceuticals position peaked at $129M in Q1 2014.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.